Welcome to our dedicated page for Hims & Hers Health SEC filings (Ticker: HIMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hims & Hers Health, Inc. filings document the regulatory record for a public consumer telehealth company offering access to health-and-wellness treatments through its digital platform. Its disclosures include operating and financial results, shareholder letters, material-event reports and clinical or regulatory updates related to products and services available through the platform, including weight loss care.
Proxy and 8-K filings cover board elections, executive compensation, shareholder voting matters, governance practices and capital-structure disclosures. The filing record also documents Class A common stock matters, share repurchase authorizations, material agreements, Regulation FD disclosures and other events affecting the company’s public-company reporting obligations.
Andrew Dudum, identified as Chief Executive Officer, director and a 10% owner of Hims & Hers Health, Inc. (HIMS), reported a sale of Class A common stock on 08/07/2025. The Form 4 shows a disposition of 660,000 shares reported as a sale (code S) at an average weighted price of $50.582 per share.
The filing itemizes the reporting person’s remaining beneficial holdings held indirectly through multiple trusts. The form shows 2,214,769 shares noted alongside the Dudum Family Heritage Trust, and additional indirect trust holdings listed as 1,194,545, 990,410, 1,286,627, 534,491, 186,723, 190,126, 321,657, 1,584,506 and 829,185 shares. The Form 4 was signed by an attorney-in-fact.
Form 144 notice: The filing reports a proposed sale of 2,572 Class A shares of Hims & Hers Health, Inc. through Fidelity Brokerage Services LLC on 08/11/2025, with an aggregate market value of $132,818.08. The company has 217,641,958 shares outstanding. The 2,572 shares were acquired on 06/15/2025 through restricted stock vesting from the issuer and were recorded as compensation.
The filing also lists recent sales by Soleil Boughton over the prior three months: seven transactions between 05/12/2025 and 07/28/2025 totaling 22,207 shares for aggregate gross proceeds of $1,228,936.95. The form includes the standard insider representation regarding material nonpublic information.
Hims & Hers Health director David B. Wells was granted 3,656 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Class A common stock. The award is recorded with a $0 per‑unit price and is reported as direct beneficial ownership. The RSUs vest upon continuous service on the earlier of the company’s 2026 annual meeting or June 15, 2026, and the transaction date on the form is 08/06/2025. The filing documents a routine equity grant to a director with vesting tied to continued service.
Christopher D. Payne, a director of Hims & Hers Health, Inc. (HIMS), was granted 3,656 Restricted Stock Units (RSUs) on 08/06/2025. Each RSU represents a contingent right to receive one share of Class A common stock, and the reported beneficial ownership following the grant is 3,656 shares held directly.
The RSUs vest upon the earlier of the company’s 2026 annual meeting of stockholders or June 15, 2026, and are subject to continuous service. The award carries no exercise price and converts one-for-one into Class A common stock when vested, increasing the director’s direct equity stake but remaining subject to standard service and vesting conditions.
Andrea Perez Garcia, identified as a Director of Hims & Hers Health, Inc. (HIMS), was granted 3,656 Restricted Stock Units (RSUs) with an indicated price of $0 on 08/06/2025. The Form 4 reports the award as a derivative security and shows 3,656 shares beneficially owned following the transaction, held in a direct ownership form.
The filing explains each RSU is a contingent right to receive one share of Class A Common Stock and that the RSUs will vest on the earlier of the 2026 annual meeting of stockholders or June 15, 2026, subject to continuous service. The Form 4 was signed by an attorney-in-fact on 08/08/2025.
Cosgrove Delos M., a director of Hims & Hers Health, Inc. (HIMS), was granted 3,656 Restricted Stock Units (RSUs) on 08/06/2025. Each RSU represents a contingent right to receive one share of Class A Common Stock, with an indicated price of $0 per unit. Following the grant, the reporting person beneficially owns 3,656 shares on a direct basis.
The RSUs vest subject to continuous service on the earlier of the company’s 2026 annual meeting of stockholders or June 15, 2026, so the award is structured as a near-term retention/compensation award that will convert into ordinary shares if service conditions are met.
Hims & Hers Health director Deborah M. Autor was granted 3,656 Restricted Stock Units (RSUs) that convert one-for-one into Class A common shares. The award was recorded as an acquisition of derivative securities and increases her direct beneficial ownership to 3,656 shares at a reported price of $0. The RSUs are subject to a service-based vesting schedule and will vest on the earlier of the company’s 2026 annual meeting or June 15, 2026, provided continuous service.
This filing reflects an equity grant to a board director rather than a cash transaction or sale, creating potential alignment between the director and shareholders through future ownership if vesting conditions are met.
Carroll Patrick Harrison, Chief Medical Officer and a director of Hims & Hers Health, Inc. (HIMS), reported the sale of 60,000 shares of Class A common stock on 08/06/2025 at a weighted average price of $53.5813 per share (sales ranged from $53.19 to $53.97). After the sale his direct beneficial ownership of Class A shares is reported as 169,940 shares.
The filing also discloses a grant of 3,656 Restricted Stock Units (RSUs) that each convert into one share of Class A common stock subject to continuous service; the RSUs vest on the earlier of the 2026 annual meeting of stockholders or June 15, 2026. The filer represents the sale price as an average weighted price and offers to provide further allocation details upon request.
Hims & Hers director Manuel Anja was granted 3,656 Restricted Stock Units (RSUs) on 08/06/2025, each representing a contingent right to one share of Class A common stock. The filing reports 3,656 shares beneficially owned following the grant and lists the ownership form as Direct (D). Vesting requires continuous service and occurs at the earlier of the company 27s 2026 annual meeting or June 15, 2026, meaning the award will convert to shares only if service continues until that event. The grant specifies a $0 price for the RSUs and does not include performance-based conditions in the explanation provided.
Hims & Hers Health, Inc. disclosed that director Schultz Kare was granted 3,656 restricted stock units (RSUs), each representing a contingent right to receive one share of Class A common stock. The RSUs vest subject to continuous service on the earlier of the company’s 2026 annual meeting or June 15, 2026, and will convert into 3,656 Class A shares upon vesting. The report shows the award is held in direct form and reflects equity-based, time‑based compensation for a board member rather than a cash transaction or sale. Without information on total outstanding shares, the absolute size of this grant limits assessment of materiality, but the filing documents a routine director equity award and alignment of the director’s interests with long‑term shareholder value.